Arlene Naranjo

Also affiliated with University of Florida, Children's Oncology Group

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 28 papers. Top paper: “Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations”.

Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations

Nature Communications(2020)10.1038/s41467-020-18987-4

N/A

3.7DataRank · unranked

175 citations

Yanling Liu, Xiaotu Ma, Alexander M. Gout, Kohei Hagiwara, Xin Zhou +19 more

MYCN amplification and ATRX mutations are incompatible in neuroblastoma

Nature Communications(2020)10.1038/s41467-020-14682-6

N/A

0.731DataRank · unranked

130 citations

Sara M. Federico, Xiang Chen, Yiping Fan, Beisi Xu, Elizabeth Stewart +32 more

Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future

JCO Clinical Cancer Informatics(2020)10.1200/cci.20.00074

N/A

0.646DataRank · unranked

73 citations

Sara M. Federico, Wendy B. London, Arlene Naranjo, Meredith S. Irwin, Samuel L. Volchenboum +2 more

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-006530

N/A

0.601DataRank · unranked

17 citations

Mitch B Diccianni, Rajen Mody, Arlene Naranjo, Fan F. Zhang, Jen Birstler +15 more

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.03.006

N/A

0.529DataRank · unranked

33 citations

Arlene Naranjo, Rochelle Bagatell, Steven G. DuBois, Jeannine S. McCune, Sheena C. Tenney +17 more

Mentoring in Pediatric Oncology

Journal of Pediatric Hematology/Oncology(2013)10.1097/mph.0b013e31829eec33

N/A

0.477DataRank · unranked

23 citations

Kimberly A. Pyke-Grimm, Dean A. Lee, Shana L. Palla, Arlene Naranjo, Giselle Saulnier Sholler +11 more

Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the Children's Oncology Group

Pediatric Blood & Cancer(2023)10.1002/pbc.30418

N/A

0.360DataRank · unranked

10 citations

Marguerite T. Parisi, Barry L. Shulkin, Brian LaBarre, Rochelle Bagatell, Lisa Diller +9 more

Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma

Cell Reports(2023)10.1016/j.celrep.2023.112879

N/A

0.345DataRank · unranked

9 citations

Erez Greenstein, Martin L. Buchkovich, Ayelet Peres, Eric Santoni‐Rugiu, Lei Yang +16 more

A subset of image‐defined risk factors predict completeness of resection in children with high‐risk neuroblastoma: An international multicenter study

Pediatric Blood & Cancer(2024)10.1002/pbc.31218

N/A

0.292DataRank · unranked

6 citations

Rochelle Bagatell, Kieran McHugh, Arlene Naranjo, Collin Van Ryn, Yesenia Rojas +20 more

Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children’s Oncology Group (COG) risk stratification.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10013

N/A

0.104DataRank · unranked

1 citations

Hannah Bender, Meredith S. Irwin, Michael D. Hogarty, Robert P. Castleberry, John M. Maris +4 more

Impact of diagnostic and end-of-induction Curie scores in tandem autologous hematopoietic cell transplant for patients with high-risk neuroblastoma: A report from the Children’s Oncology Group.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10027

N/A

0DataRank · unranked

0 citations

Marguerite T. Parisi, Barry L. Shulkin, Brian LaBarre, Rochelle Bagatell, Lisa Diller +9 more

Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10523

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Wendy B. London, Sheena C. Tenney +11 more

Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

(2023)10.1158/1078-0432.c.6531294

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

(2023)10.1158/1078-0432.c.6531294.v1

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high‐risk neuroblastoma clinical trial

Pediatric Blood & Cancer(2023)10.1002/pbc.30658

N/A

0DataRank · unranked

0 citations

Huiyun Wu, Jianrong Wu, Arlene Naranjo, Vinay M. Daryani, Amar Gajjar +3 more

Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology

npj Precision Oncology(2024)10.1038/s41698-024-00745-0

N/A

0DataRank · unranked

16 citations

Emma Dyer, Monica Pomaville, Kristina Doytcheva, James M. Dolezal, Sara Kochanny +16 more

Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531

Journal of Pediatric Surgery(2024)10.1016/j.jpedsurg.2024.161896

N/A

0DataRank · unranked

6 citations

E. Stanton Adkins, Peter Mattei, Fredric A. Hoffer, Sandra L. Wootton‐Gorges, Wendy B. London +14 more

Late cognitive and adaptive outcomes of patients with neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia‐syndrome: A report from the Children's Oncology Group

Pediatric Blood & Cancer(2024)10.1002/pbc.31039

N/A

0DataRank · unranked

2 citations

Victoria W. Willard, Leanne Embry, Arlene Naranjo, Brian LaBarre, Katherine K. Matthay +2 more

Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531

Pediatric Blood & Cancer(2024)10.1002/pbc.31407

N/A

0DataRank · unranked

1 citations

Howard M. Katzenstein, Arlene Naranjo, Sheena C. Tenney, Lulu Chen, Wendy B. London +11 more

Impact of an objective scoring system on initiation of therapy in patients with International Neuroblastoma Risk Group Staging System (INRGSS) stage MS neuroblastoma: A report from the Children’s Oncology Group.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.10003

N/A

0DataRank · unranked

1 citations

Navin Pinto, Arlene Naranjo, Jed G. Nuchtern, Edward F. Attiyeh, Rochelle Bagatell +12 more

Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology

Research Square(2024)10.21203/rs.3.rs-4396782/v1

N/A

0DataRank · unranked

1 citations

Siddhi Ramesh, Emma Dyer, Monica Pomaville, Kristina Doytcheva, James M. Dolezal +13 more

Healthcare utilization disparities among children with high‐risk neuroblastoma treated on Children's Oncology Group clinical trials

Pediatric Blood & Cancer(2024)10.1002/pbc.31192

N/A

0DataRank · unranked

0 citations

Yimei Li, Kelly Getz, Yuan‐Shung Huang, Matt Hall, Arlene Naranjo +12 more

Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients ≥18 months with unfavorable histology and without MYCN amplification: A Children’s Oncology Group (COG) report.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10502

N/A

0DataRank · unranked

0 citations

Arlene Naranjo, Emily Hibbitts, Xiangming Ding, Rachelle Tibbetts, Rebekah Kennedy +7 more

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3909

N/A

0DataRank · unranked

216 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group

European Journal of Cancer(2020)10.1016/j.ejca.2020.04.007

N/A

0DataRank · unranked

31 citations

Arlene Naranjo, Emily Hibbitts, Julie M. Gastier‐Foster, Rochelle Bagatell, Meredith S. Irwin +5 more

Predicting response to chemotherapy in neuroblastoma using deep learning: A report from the International Neuroblastoma Risk Group.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10039

N/A

0DataRank · unranked

2 citations

Diana Michael, Liu Liu, Nicholas Feinberg, Meaghan Granger, Arlene Naranjo +5 more

Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.12.14.471886

N/A

0DataRank · unranked

0 citations

Erez Greenstein, Martin L. Buchkovich, Martin Mikl, Ayelet Peres, Eric Santoni‐Rugiu +13 more

Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project

Pediatric Blood & Cancer(2022)10.1002/pbc.29616

N/A

0DataRank · unranked

14 citations

Steven G. DuBois, John Neuhaus, Steve Braunstein, Brent R. Weil, Arlene Naranjo +4 more